Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
about
Pathobiology of pulmonary arterial hypertension and right ventricular failureThe genetics of pulmonary arterial hypertensionNovel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension.Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertensionPulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene.Pulmonary arterial hypertension associated with systemic sclerosis.Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency.Pulmonary arteriovenous malformations.Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.The genetics of pulmonary arterial hypertension in the post-BMPR2 era.Accurate genetic diagnosis of Finnish pulmonary arterial hypertension patients using oligonucleotide-selective sequencing.The intersection of genes and environment: development of pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia and stimulant exposure.Oxidative stress contributes to endothelial dysfunction in mouse models of hereditary hemorrhagic telangiectasia.Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension.Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.Endoglin: a critical mediator of cardiovascular healthA novel channelopathy in pulmonary arterial hypertension.Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-β signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts.Relevant issues in the pathology and pathobiology of pulmonary hypertension.Pulmonary veno-occlusive disease: advances in clinical management and treatments.Update on pulmonary vascular diseases 2010.Clinical and molecular genetic features of hereditary pulmonary arterial hypertension.STAT3 signaling in pulmonary arterial hypertension.The genetic basis of pulmonary arterial hypertension.Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.Pericytes as targets in hereditary hemorrhagic telangiectasia.Molecular pathogenesis and current pathology of pulmonary hypertension.Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.The role of genetics in pulmonary arterial hypertension.Discovery of a murine model of clinical PAH: Mission impossible?Inhibition of apelin expression by BMP signaling in endothelial cells.Pulmonary hypertension in hereditary haemorrhagic telangiectasia.
P2860
Q26821779-DFA36177-F880-4ECB-9A63-35C4FCB68299Q27027507-21D72D94-8355-4F27-ADCD-EC65C8FC6A2AQ33769113-77EAE213-68FD-405C-A675-58EDBD5ADD7FQ33793407-47074F4E-E299-42FB-AB7B-3D6B08EE244EQ33968765-4E950C87-C191-4198-9089-14E0A6FFD8E0Q34339756-4B0660AA-D39F-4296-B241-1A4A4640171DQ34414793-ED2318C6-6006-415A-8A00-B7C45352E5C7Q35002423-80FECF4C-5C0A-460F-AF78-08DEBBFD3542Q35022813-2503A2E1-1292-4F57-801B-36346DDAC3EDQ35044725-665A2644-7122-4C03-870E-1CBB350D483EQ35082312-90EDA65A-4245-4923-AFBC-91B26D12C160Q35181115-1DC54535-7B9D-4CAF-9AFE-C091A4FC567DQ35185797-963D24AF-0C43-4294-A75B-A1BE4600BB10Q35573919-7A52B4C6-39ED-4328-95C9-9A0DB0D2BE5AQ35907757-8E1F0463-D308-4CF5-A4B5-13B746EEE363Q36009075-626FEE0B-9D23-41F0-A41D-EE0EAB0CD6C8Q36520793-FCDD54B8-81CD-4CA4-B679-B8B257803243Q36541797-2B50FE7C-1023-4EF8-BF9D-7771023AF219Q36769101-92326F66-2ABC-4642-A7E9-FAF5AA18A8B5Q36825271-57B161FE-96A3-4D0D-9D41-264BE61D5187Q37219463-84AA3F61-930B-4BB8-B637-DB0F0C8F2DFAQ37298006-EF2879DD-6B18-4CF6-92CB-D0E005F3945DQ37475655-3DC44D7C-0A18-4565-BABB-5EF5A42E9DD9Q37479646-00867D22-B6E4-499C-9988-FBC7A90A1792Q37563414-624D90C1-AE10-42BF-97C7-24B78E1B58EEQ37673917-2E16349D-5804-4C66-B802-B9F7A3ADEB67Q37867672-BFE5CEAB-8E48-46C1-A958-040CEAC333BCQ37898899-AE77EFCE-0459-490F-A632-4078E82D86BDQ38111740-AF66A7DD-5A48-4FC2-AEDE-51AB87AF7C40Q38140894-76218ED1-B8B0-407E-A71E-863EB96D3DA5Q38179984-6A5876C7-54D9-4BDC-B1A2-9193C02E675CQ38332401-9D5696DE-03B8-47BD-9454-BBAF6B4F5177Q38374758-AC49B3AB-E2D1-4007-818D-46E0B6AFF166Q38676413-F7D38725-DDD1-412A-BA54-8D6BA5C5CE50Q38779774-371200A0-A62D-434F-8345-881908C06704Q38817806-72C95F6E-9474-4BDF-ACEC-8CFCBEDA7207Q38988081-BD70C324-AC3D-4ADC-BA43-EBF5C1B1E899Q39089351-99212B19-F1D9-4A86-9A67-07EC4172915DQ39297087-978F96FE-0168-48FB-8C6D-5C6832E4EA60Q40874747-E02FBA79-AAAB-4FAF-8CBC-5E996C87C21A
P2860
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Clinical outcomes of pulmonary ...... ing an ACVRL1 (ALK1) mutation.
@en
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1
@nl
type
label
Clinical outcomes of pulmonary ...... ing an ACVRL1 (ALK1) mutation.
@en
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1
@nl
prefLabel
Clinical outcomes of pulmonary ...... ing an ACVRL1 (ALK1) mutation.
@en
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1
@nl
P2093
P2860
P50
P1476
Clinical outcomes of pulmonary ...... ing an ACVRL1 (ALK1) mutation.
@en
P2093
Abilio Reis
Alain Fraisse
Azzeddine Yaici
Barbara Girerd
Benjamin Sztrymf
David Tregouet
Dermot S O'Callaghan
Florence Coulet
Florent Soubrier
Gérald Simonneau
P2860
P304
P356
10.1164/RCCM.200908-1284OC
P407
P577
2010-01-07T00:00:00Z